Compare NMTC & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | INCR |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 47.4M |
| IPO Year | 2010 | 2021 |
| Metric | NMTC | INCR |
|---|---|---|
| Price | $3.71 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.90 | N/A |
| AVG Volume (30 Days) | ★ 31.0K | 26.8K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,097,692.00 | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | $31.90 | $41.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.47 | N/A |
| 52 Week Low | $0.55 | $0.68 |
| 52 Week High | $5.40 | $1.77 |
| Indicator | NMTC | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 56.86 |
| Support Level | $0.69 | $0.86 |
| Resistance Level | $4.87 | $0.89 |
| Average True Range (ATR) | 0.37 | 0.04 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 5.66 | 75.33 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.